Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Reblozyl as a treatment for adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Upon approval, this would represent the fourth authorized indication for Reblozyl in the EU.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers Squibb’s $11 Billion Notes Issuance for Acquisitions
- Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)
- Truist biotech analysts hold an analyst/industry conference call
- Aurora Cannabis CFO Glen Ibbott to step down, Simona King to succeed
- Bristol Myers says FDA accepts sNDA for KRAZATI in combination with cetuximab
